• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Shannon Ellis

Articles by Shannon Ellis

CNDA Town Hall: New drug commissioner Hong promises continued innovation support

May 31, 2018
By Shannon Ellis
BEIJING – Freshly installed Commissioner Jiao Hong of the China National Drug Administration, formerly the CFDA, voiced the agency's plans to streamline review and approval of new drugs, encourage innovation, improve capacity to take a science-based approach, deepen industry's quality control efforts and step up monitoring of adverse events.
Read More

China moves fast to adopt global standards; implementing to scale remains a challenge

May 30, 2018
By Shannon Ellis
SHANGHAI – Reform is not a word that the Chinese government shies away from. That has been particularly true for China's pharmaceutical industry. Since 2015, the government has been tackling widespread and impressive reforms, not the least of which was joining the International Council of Harmonization (ICH) last summer, accelerating the country's ability to align its system with international norms.
Read More

China moves fast to adopt global standards; implementing to scale remains a challenge

May 25, 2018
By Shannon Ellis
SHANGHAI – Reform is not a word that the Chinese government shies away from. That has been particularly true for China's pharmaceutical industry. Since 2015, the government has been tackling widespread and impressive reforms, not the least of which was joining the International Council of Harmonization (ICH) last summer, accelerating the country's ability to align its system with international norms.
Read More

China's I-O race getting hotter as Mabspace closes $40M series B financing

May 16, 2018
By Shannon Ellis
SHANGHAI – Chinese antibody discovery biotech Mabspace Biosciences Co. Ltd., of Suzhou, has raised $40 million in series B financing to further pursue its immuno-oncology (I-O) ambitions. Founded in 2013, the startup has proved itself to be relatively careful with money. Its last round of financing was three years ago, when Mabspace raised $15 million from Lilly Asia Ventures (an independent venture fund, once a part of Eli Lilly and Co.).
Read More

China's Cstone raises $260M series B round for I-O pipeline

May 15, 2018
By Shannon Ellis

SHANGHAI – Suzhou-based Cstone Pharmaceuticals Co. Ltd. continues to wow observers, having obtained the largest series B financing for a Chinese biotech to date, raising $260 million in venture capital financing. That follows a record-breaking series A in July 2016 for $150 million.


Read More

China's I-O race getting hotter as Mabspace closes $40M series B financing

May 15, 2018
By Shannon Ellis
SHANGHAI – Chinese antibody discovery biotech Mabspace Biosciences Co. Ltd., of Suzhou, has raised $40 million in series B financing to further pursue its immuno-oncology (I-O) ambitions. Founded in 2013, the startup has proved itself to be relatively careful with money. Its last round of financing was three years ago, when Mabspace raised $15 million from Lilly Asia Ventures, (an independent venture fund, once a part of Eli Lilly and Co.).
Read More

China's Cstone raises $260M series B round for I-O pipeline

May 14, 2018
By Shannon Ellis
SHANGHAI – Suzhou-based Cstone Pharmaceuticals Co. Ltd. continues to wow observers, having obtained the largest series B financing for a Chinese biotech to date, raising $260 million in venture capital financing. That follows a record-breaking series A in July 2016 for $150 million.
Read More

Cross-border partnering activity propels China's biotech sector

May 2, 2018
By Shannon Ellis
SUZHOU, China – It is no secret that the fortunes of China's biotech sector have never looked brighter. There is a list of reasons – recent regulatory reforms, unwavering government financial support, vast amounts of venture capital, legions of young doctorates and a huge untapped market. But without cross-border partnering, China's biotech industry would look dramatically different.
Read More

Cross-border partnering propels China's biotech sector

April 27, 2018
By Shannon Ellis
SUZHOU, China – It is no secret that the fortunes of China's biotech sector have never looked brighter. There is a list of reasons – recent regulatory reforms, unwavering government financial support, vast amounts of venture capital, legions of young doctorates and a huge untapped market. But without cross-border partnering, China's biotech industry would look dramatically different.
Read More

China's money hose keeping the biotech sector well-watered

April 25, 2018
By Shannon Ellis
SUZHOU, China – It is a tradition at the annual ChinaBio Partnering Conference that Greg Scott, event founder and organizer, kicks things off with a slideshow to walk participants – biotech and med-tech entrepreneurs, venture capital investors and big pharma – through an impressive China money story. The numbers can surprise even Scott, who has been bearing witness and contributing to the industry's growth for the last decade.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe